drugset / Trial / NCT04475042

Stratified Treatment to Ameliorate Diastolic Left Ventricular Stiffness in Heart Failure With Preserved Ejection Fraction

NCT04475042

Phase 2 Unknown 26 enrolled Mariëlle Scheffer AstraZeneca · collab
RandomizedCrossoverQuadruple-blindTreatment

Summary

A 35-week, single-center, prospective, double-blind, controlled, randomized, 2x2 crossover, interventional Phase II study, investigating the effect of treatment with dapagliflozin 10mg od on Left Ventricular distensibility in patients with early HFpEF.

Timeline

Start
2020-07-01
Primary completion
2021-11
Completion
2022-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dapagliflozin Small molecule 10 mg